Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Acq. announced
Appointed director
Quarterly results
Consulting agrmnt
Ardea Biosciences, Inc. (RDEA) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2011 8-K Quarterly results
Docs: "Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results SAN DIEGO, May 9, 2011 — Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the first quarter ended March 31, 2011. “Results from our recently completed Phase 2b study of lesinurad in combination with allopurinol demonstrate lesinurad's potential to bring relief to millions of patients currently suffering with gout,” commented Barry D. Quart, PharmD, Ardea's president and chief executive officer. “We look forward to presenting additional results from this study at the Annual European Congress of Rheumatology in May and discussing our ..."
05/07/2010 8-K Quarterly results
Docs: "Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2010 Financial Results SAN DIEGO, May 7, 2010 — Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus , today reported recent accomplishments and financial results for the first quarter ended March 31, 2010. “We are pleased to have accomplished a number of very important objectives since our last quarterly update,” commented Barry D. Quart, PharmD, president and chief executive officer of Ardea. “In March, we announced positive, preliminary top-line results from our completed Phase 2b monotherapy study of RDEA594 and, shortly thereafter, we were able to significantly strengthen our financial posit..."
05/13/2008 8-K Quarterly results
Docs: "Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results San Diego, May 9, 2008 — Ardea Biosciences, Inc. , a company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout, today announced that John W. Beck has been appointed Senior Vice President, Finance and Operations and Chief Financial Officer effective May 27, 2008. He will resign from our board of directors shortly thereafter. The Company also reported recent accomplishments and financial results for the first quarter ended March 31, 2008. Appointment of John W. Beck as Chief Financial Officer",
"Executive Employment Agreement between the Company and John W. Beck"
05/04/2006 8-K Quarterly results
Docs: "INTRABIOTICS REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS"
11/02/2005 8-K Quarterly results
Docs: "INTRABIOTICS REPORTS THIRD QUARTER 2005 FINANCIAL RESULTS"
07/21/2005 8-K Quarterly results
Docs: "INTRABIOTICS REPORTS SECOND QUARTER 2005 FINANCIAL RESULTS"
05/11/2005 8-K Quarterly results
Docs: "INTRABIOTICS REPORTS FIRST QUARTER 2005 FINANCIAL RESULTS AND DECISION TO SUSPEND ACTIVE EVALUATION OF STRATEGIC ALTERNATIVES"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy